Brief: 180 Life Sciences Says FDA Declined To Grant Meeting About Prelim Discussion For Dupuytren's Disease Treatment

Forum Markets

28/03/2022 14:30

March 28 (Reuters) - 180 Life Sciences Corp  ATNF.O :
    * 180 LIFE SCIENCES -  FDA GAVE NOTICE THAT FDA DECLINED TO
GRANT
MEETING WITH CO ABOUT PRELIMINARY DISCUSSION FOR TREATMENT OF
EARLY STAGE DUPUYTREN'S DISEASE
    * 180 LIFE SCIENCES CORP - FDA HAD DECLINED TO GRANT TYPE C
MEETING UNTIL MORE INFORMATION ABOUT MANUFACTURER OF PRODUCT IS
PROVIDED
    * 180 LIFE SCIENCES - UPON ADVICE OF ITS REGULATORY
CONSULTANTS
PLANS TO FURTHER CORRESPOND WITH FDA WITH GOAL OF HAVING A TYPE
C MEETING WITH FDA

Further company coverage:  ATNF.O 

 ((Reuters.Briefs@thomsonreuters.com;))